TrialSignal
Clinical trial intelligence report
A Phase 1, Open-label, Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT05477186-Jul 28, 2026
NCT ID
NCT05477186
Status
COMPLETED
Phase
Phase 1
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
GlaxoSmithKline's CV0501 mRNA COVID-19 vaccine is positioned as a booster option for individuals previously vaccinated with Comirnaty or Moderna vaccines. Given the ongoing need for booster vaccinations due to waning immunity and emerging variants, this asset could capture a significant share of the booster market. The competitive landscape includes established players like Pfizer-BioNTech and Moderna, as well as emerging mRNA candidates. Successful safety and immunogenicity results could enhance GSK's portfolio and strengthen its position in the rapidly evolving vaccine market.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05477186
Indication
COVID-19
Modality
vaccine
Target
mRNA-based vaccine targeting SARS-CoV-2 spike protein.
Intervention
CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (100 μg), CV0501 (200 μg)
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.